Cipher Pharmaceuticals (CPH) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered consistent revenue, earnings, and cash flow from legacy U.S. and Canadian operations, with revenue at $5.3M, product revenue up 18%, and licensing revenue down 25%.

• Acquisition of Natroba and its U.S. commercial infrastructure marks a new growth phase, with Natroba addressing unmet needs in head lice and scabies treatment and FDA exclusivity until 2033.

• MOB-015 nail fungus treatment achieved market leadership in Sweden with a 36% share and is expected to launch in Canada in 2026.

• Net income for Q2 2024 was $3.0M, with EPS of $0.12, nearly unchanged from Q2 2023.

• Management changes effective August 10, 2024: Bryan Jacobs becomes President, Ryan Mailling appointed CFO.

Financial highlights

• Q2 2024 total revenue was $5.3M; six-month revenue was $11.2M.

• Product sales for Q2 were $3.7M, up 18% year-over-year; six-month product sales were $7M, up 10%.

• Q2 licensing revenue was $1.6M, down 25% year-over-year; six-month licensing revenue up 10%.

• Adjusted EBITDA for Q2 and six months was $3.1M and $6.6M, respectively, both up from prior year; EBITDA margin impacted by $0.8M in unrealized foreign exchange losses.

• Cash and cash equivalents rose to $48M as of June 30, 2024.

Outlook and guidance

• Natroba expected to drive significant U.S. and global growth, with licensing discussions underway for Europe and Asia.

• First Canadian sales of MOB-015 anticipated in H2 2026, targeting a CAD 92M market; further clinical data expected in January 2025.

• Licensing deals for Natroba outside the U.S. anticipated within 12 months.

• Focus on integrating the Natroba acquisition and launching complementary dermatology products.